|
page 1/17
|
| |
|
Abe T, Matsumoto C, Shimada E, Mazda T, Takanashi M, Kawaguchi K, Hamasaki T, Mita H, Akiyama K, Okazaki H, Satake M, Tadokoro K. Immunoglobulin E oligomers identified in blood components activate mast cells: relevance to anaphylactic transfusion reaction. Transfusion. 2011;51:2327-2336. Thèmes : Hémovigilance et sécurité transfusionnelle ; maj-2012-02

|
|
|
|
|
|
|
Alexander ET, Towery JA, Miller AN, Kramer C, Hogan KR, Squires JE, Stuart RK, Costa LJ. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function. Transfusion. 2011;51:1995-2000. Thèmes : Thérapie cellulaire ; maj-2012-02

|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Atreya C, Nakhasi H, Mied P, Epstein J, Hughes J, Gwinn M, Kleinman S, Dodd R, Stramer S, Walderhaug M, Ganz P, Goodrich R, Tibbetts C, Asher D. FDA workshop on emerging infectious diseases: evaluating emerging infectious diseases (EIDs) for transfusion safety. Transfusion. 2011;51:1855-1871. Thèmes : Epidémiologie ; maj-2012-02

|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
page 1/17
|